KWR Stock Analysis: Quaker Chemical | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.799m USD | 12M Return: 18.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.5M
EPS Trend: -45.9%
Qual. Beats: 0
Rev. Trend: -59.3%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Quaker Chemical Corporation (NYSE: KWR), operating as Quaker Houghton, is a global specialty chemicals company headquartered in Conshohocken, Pennsylvania. Founded in 1918, the firm develops, produces, and markets formulated specialty chemical products-primarily industrial process fluids-and offers chemical management services to heavy industrial and manufacturing customers. Operating within the GICS Materials sector (Specialty Chemicals sub-industry), the company is classified as a mid-cap stock with a market capitalization of approximately $2.6 billion.
The companys product portfolio spans metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die cast mold releases, heat treatment and quenchants, metal forging and hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, and rod and wire drawing fluids. These offerings serve a diverse base of steel, aluminum, automotive, aerospace, offshore, container, mining, and metalworking customers.
Quaker Houghton combines a specialty chemicals manufacturing model with a service-oriented chemical management business, supplying consumable inputs that are critical to its customers production processes rather than being part of the final product. This positioning typically ties the companys revenue closely to global industrial activity and metalworking demand.
- Global industrial slowdown pressures metalworking fluid volumes
- Petroleum-based raw material costs compress specialty chemical margins
- M&A integration and pricing actions support margin recovery
| Net Income: 4.26m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.51 > 1.0 |
| NWC/Revenue: 29.29% < 20% (prev 29.77%; Δ -0.48% < -1%) |
| CFO/TA 0.05 > 3% & CFO 143.3m > Net Income 4.26m |
| Net Debt (749.0m) to EBITDA (168.8m): 4.44 < 3 |
| Current Ratio: 2.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.4m) vs 12m ago -1.87% < -2% |
| Gross Margin: 34.38% > 18% (prev 36.72%; Δ -2.35% > 0.5%) |
| Asset Turnover: 70.47% > 50% (prev 68.04%; Δ 2.44% > 0%) |
| Interest Coverage Ratio: 1.51 > 6 (EBIT TTM 70.5m / Interest Expense TTM 46.8m) |
| A: 0.20 (Total Current Assets 952.6m - Total Current Liabilities 388.5m) / Total Assets 2.80b |
| B: 0.22 (Retained Earnings 607.5m / Total Assets 2.80b) |
| C: 0.03 (EBIT TTM 70.5m / Avg Total Assets 2.73b) |
| D: 0.97 (Book Value of Equity 1.38b / Total Liabilities 1.42b) |
| Altman-Z'' = 3.22 = A |
| DSRI: 0.99 (Receivables 441.2m/418.7m, Revenue 1.93b/1.81b) |
| GMI: 1.07 (GM 36.72% / 34.38%) |
| AQI: 0.77 (AQ_t 0.43 / AQ_t-1 0.56) |
| SGI: 1.06 (Revenue 1.93b / 1.81b) |
| TATA: -0.05 (NI 4.26m - CFO 143.3m) / TA 2.80b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 147.52 with a total of 192,349 shares traded. Over the past week, the price has changed by -7.14%, over one month by +3.01%, over three months by +15.12% and over the past year by +18.80%.
Current recommended Stop Loss: 140.40 (which is 4.8% or 1.3 ATR below the current price).
Quaker Chemical has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy KWR.
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 170.6 | 15.6% |
P/E Trailing = 619.8462
P/E Forward = 22.5225
P/S = 1.453
P/B = 2.0345
P/EG = 1.8561
Revenue TTM = 1.93b USD
EBIT TTM = 70.5m USD
EBITDA TTM = 168.8m USD
Long Term Debt = 837.1m USD (from longTermDebt, last quarter)
Short Term Debt = 37.3m USD (from shortTermDebt, last quarter)
Debt = 918.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.1m
Net Debt = 749.0m USD (calculated: Debt 918.7m - CCE 169.7m)
Enterprise Value = 3.55b USD (2.80b + Debt 918.7m - CCE 169.7m)
Interest Coverage Ratio = 1.51 (Ebit TTM 70.5m / Interest Expense TTM 46.8m)
EV/FCF = 24.86x (Enterprise Value 3.55b / FCF TTM 142.7m)
FCF Yield = 4.02% (FCF TTM 142.7m / Enterprise Value 3.55b)
FCF Margin = 7.41% (FCF TTM 142.7m / Revenue TTM 1.93b)
Net Margin = 0.22% (Net Income TTM 4.26m / Revenue TTM 1.93b)
Gross Margin = 34.38% ((Revenue TTM 1.93b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Gross Margin QoQ = 36.78% (prev 31.86%)
Tobins Q-Ratio = 1.27 (Enterprise Value 3.55b / Total Assets 2.80b)
Interest Expense / Debt = 5.09% (Interest Expense 46.8m / Debt 918.7m)
Taxrate = 26.57% (7.14m / 26.9m)
NOPAT = 51.8m (EBIT 70.5m * (1 - 26.57%))
Current Ratio = 2.45 (Total Current Assets 952.6m / Total Current Liabilities 388.5m)
Debt / Equity = 0.67 (Debt 918.7m / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 4.44 (Net Debt 749.0m / EBITDA 168.8m)
Debt / FCF = 5.25 (Net Debt 749.0m / FCF TTM 142.7m)
Total Stockholder Equity = 1.36b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.16% (Net Income 4.26m / Total Assets 2.80b)
RoE = 0.31% (Net Income TTM 4.26m / Total Stockholder Equity 1.36b)
RoCE = 3.21% (EBIT 70.5m / Capital Employed (Equity 1.36b + L.T.Debt 837.1m))
RoIC = 2.20% (NOPAT 51.8m / Invested Capital 2.35b)
WACC = 9.08% (E(2.80b)/V(3.72b) * Re(10.84%) + D(918.7m)/V(3.72b) * Rd(5.09%) * (1-Tc(0.27)))
Discount Rate = 10.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -75.02 | Cagr: -1.22%
[DCF] Terminal Value 72.25% ; FCFF base≈145.3m ; Y1≈140.6m ; Y5≈138.3m
[DCF] Fair Price = 67.97 (EV 1.93b - Net Debt 749.0m = Equity 1.18b / Shares 17.4m; r=9.08% [WACC]; 5y FCF grow -4.35% → 2.50% )
EPS Correlation: -45.91 | EPS CAGR: -3.42% | SUE: 0.0 | # QB: 0
Revenue Correlation: -59.30 | Revenue CAGR: -1.87% | SUE: 0.99 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.62 | Chg30d=+0.72% | Revisions=-57% | Analysts=7
EPS next Quarter (2026-09-30): EPS=1.95 | Chg30d=-1.06% | Revisions=-57% | Analysts=7
EPS current Year (2026-12-31): EPS=7.02 | Chg30d=+0.08% | Revisions=-57% | GrowthEPS=-0.1% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=8.77 | Chg30d=+0.05% | Revisions=-38% | GrowthEPS=+25.1% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -75% (up=1, down=16)